Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study

Lenka N.C. Boyd(Amsterdam University Medical Centers), Heinz‐Josef Klümpen(University Medical Center Groningen)

Frontiers in Pharmacology

October 18, 2023

10.3389/fphar.2023.1274692

Cited by 9

Related Papers

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|1k

Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma

|New England Journal of Medicine|2023|530

Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives

|European Journal of Cancer|2024|50

Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: A multicenter phase II trial.

|Journal of Clinical Oncology|2024|12

Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 Trial

|Journal of Clinical Oncology|2025|5